Janssen's Imbruvica Leads CLL Market Expansion In Europe

 
• By John Davis

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.  

Garden_Path
The EU development path in chronic lymphocytic leukemia is clear • Source: Shutterstock

More from Anticancer

More from Therapy Areas